12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FX006: Phase IIb data

Top-line data from a double-blind, international Phase IIb trial in 228 patients with OA of the knee showed that a single intra-articular injection of the undisclosed optimal dose of FX006 significantly improved the magnitude and duration of pain relief vs. an IR formulation of triamcinolone acetonide...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >